论文部分内容阅读
目的观察奥扎格雷钠联合依达拉奉治疗脑梗死的效果。方法将204例脑梗死的患者随机分为研究组和对照组各102例。研究组采用奥扎格雷钠联合依达拉奉进行治疗,对照组仅采用奥扎格雷钠治疗。分别于治疗7d、14d后对患者神经功能缺损程度进行评分,14d后对患者临床疗效进行判定。结果研究组总有效率为91.18%高于对照组的77.45%,差异有统计学意义(P<0.05)。2组患者治疗前神经功能缺损评分差异无统计学意义(P>0.05),治疗后7d及14d后神经功能缺损评分均低于治疗前,且逐渐降低,但研究组低于对照组,差异均有统计学意义(P<0.05)。结论奥扎格雷钠联合依达拉奉治疗脑梗死临床疗效较单纯奥扎格雷钠治疗效果好,能够显著提高患者的预后,值得临床推广应用。
Objective To observe the effect of ozagrel combined with edaravone on cerebral infarction. Methods 204 patients with cerebral infarction were randomly divided into study group and control group of 102 cases. The study group was treated with sodium ozagrel combined with edaravone, while the control group received sodium ozagrel only. The degree of neurological deficit was scored on the 7th day and the 14th day after treatment, respectively, and the clinical effect was evaluated 14 days later. Results The total effective rate was 91.18% in the study group and 77.45% in the control group, the difference was statistically significant (P <0.05). There was no significant difference in neurological deficit score between the two groups before treatment (P> 0.05), and the scores of neurological deficit after 7d and 14d after treatment were lower than those before treatment and gradually decreased, but the study group was lower than that of the control group There was statistical significance (P <0.05). Conclusions Ozagrel sodium combined with edaravone has a better curative effect than ozagrel sodium in treating cerebral infarction, which can significantly improve the prognosis of patients. It is worthy of clinical application.